All lobbying filings

TIBER CREEK GROUP

Lobbying for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Pharmaceutical company.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to S. 3267 - ASAP Act.

Health Issues

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.

Bills named in this filing 6

S. 3267
ASAP Act
H.R. 6509
SAFE Drugs Act of 2025
S. 3794
SAFE Drugs Act of 2026
S. 1041
Affordable Prescriptions for Patients Act
S. 1096
Preserve Access to Affordable Generics and Biosimilars Act
S. 2658
Medication Affordability and Patent Integrity Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.